Avanos Medical Statistics
Total Valuation
Avanos Medical has a market cap or net worth of $568.14 million. The enterprise value is $630.64 million.
Important Dates
The next estimated earnings date is Monday, May 5, 2025, before market open.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Avanos Medical has 46.00 million shares outstanding. The number of shares has decreased by -1.29% in one year.
| Current Share Class | 46.00M |
| Shares Outstanding | 46.00M |
| Shares Change (YoY) | -1.29% |
| Shares Change (QoQ) | -1.29% |
| Owned by Insiders (%) | 1.78% |
| Owned by Institutions (%) | 88.71% |
| Float | 42.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 10.98 |
| PS Ratio | 0.83 |
| Forward PS | 0.82 |
| PB Ratio | 0.69 |
| P/TBV Ratio | 2.18 |
| P/FCF Ratio | 6.85 |
| P/OCF Ratio | 5.64 |
| PEG Ratio | 1.26 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 6.98, with an EV/FCF ratio of 7.61.
| EV / Earnings | n/a |
| EV / Sales | 0.92 |
| EV / EBITDA | 6.98 |
| EV / EBIT | 14.08 |
| EV / FCF | 7.61 |
Financial Position
The company has a current ratio of 2.37, with a Debt / Equity ratio of 0.21.
| Current Ratio | 2.37 |
| Quick Ratio | 1.45 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 1.63 |
| Debt / FCF | 2.05 |
| Interest Coverage | 3.67 |
Financial Efficiency
Return on equity (ROE) is -37.42% and return on invested capital (ROIC) is 2.29%.
| Return on Equity (ROE) | -37.42% |
| Return on Assets (ROA) | 1.97% |
| Return on Invested Capital (ROIC) | 2.29% |
| Return on Capital Employed (ROCE) | 4.53% |
| Revenue Per Employee | $308,846 |
| Profits Per Employee | -$176,066 |
| Employee Count | 2,227 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 2.03 |
Taxes
| Income Tax | -17.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.99% in the last 52 weeks. The beta is 1.15, so Avanos Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.15 |
| 52-Week Price Change | -33.99% |
| 50-Day Moving Average | 14.21 |
| 200-Day Moving Average | 18.90 |
| Relative Strength Index (RSI) | 37.55 |
| Average Volume (20 Days) | 490,992 |
Short Selling Information
The latest short interest is 934,184, so 2.03% of the outstanding shares have been sold short.
| Short Interest | 934,184 |
| Short Previous Month | 796,523 |
| Short % of Shares Out | 2.03% |
| Short % of Float | 2.22% |
| Short Ratio (days to cover) | 1.73 |
Income Statement
In the last 12 months, Avanos Medical had revenue of $687.80 million and -$392.10 million in losses. Loss per share was -$8.53.
| Revenue | 687.80M |
| Gross Profit | 381.30M |
| Operating Income | 44.80M |
| Pretax Income | 14.70M |
| Net Income | -392.10M |
| EBITDA | 90.30M |
| EBIT | 44.80M |
| Loss Per Share | -$8.53 |
Full Income StatementBalance Sheet
The company has $107.70 million in cash and $170.20 million in debt, giving a net cash position of -$62.50 million or -$1.36 per share.
| Cash & Cash Equivalents | 107.70M |
| Total Debt | 170.20M |
| Net Cash | -62.50M |
| Net Cash Per Share | -$1.36 |
| Equity (Book Value) | 828.50M |
| Book Value Per Share | 18.03 |
| Working Capital | 227.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $100.70 million and capital expenditures -$17.80 million, giving a free cash flow of $82.90 million.
| Operating Cash Flow | 100.70M |
| Capital Expenditures | -17.80M |
| Free Cash Flow | 82.90M |
| FCF Per Share | $1.80 |
Full Cash Flow StatementMargins
Gross margin is 55.44%, with operating and profit margins of 6.51% and -57.01%.
| Gross Margin | 55.44% |
| Operating Margin | 6.51% |
| Pretax Margin | -58.64% |
| Profit Margin | -57.01% |
| EBITDA Margin | 13.13% |
| EBIT Margin | 6.51% |
| FCF Margin | 12.05% |